Guggenheim Lowers Adaptimmune Therapeutics (NASDAQ:ADAP) to Neutral

Guggenheim downgraded shares of Adaptimmune Therapeutics (NASDAQ:ADAP) from a buy rating to a neutral rating in a report published on Thursday, BenzingaRatingsTable reports.

ADAP has been the topic of several other research reports. BidaskClub cut Adaptimmune Therapeutics from a hold rating to a sell rating in a research note on Friday, July 26th. Svb Leerink reaffirmed a market perform rating and set a $5.00 target price (down previously from $12.00) on shares of Adaptimmune Therapeutics in a research note on Tuesday, May 7th. Leerink Swann cut Adaptimmune Therapeutics from an outperform rating to a market perform rating and set a $4.15 target price on the stock. in a research note on Tuesday, May 7th. Citigroup reaffirmed a buy rating and set a $8.00 target price on shares of Adaptimmune Therapeutics in a research note on Thursday, May 30th. Finally, Raymond James lowered their target price on Adaptimmune Therapeutics from $16.00 to $6.00 and set an outperform rating on the stock in a research note on Tuesday, May 7th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Adaptimmune Therapeutics currently has a consensus rating of Buy and a consensus target price of $6.59.

Shares of ADAP opened at $2.51 on Thursday. The business has a 50-day moving average of $3.52. Adaptimmune Therapeutics has a 1-year low of $2.26 and a 1-year high of $14.54. The company has a debt-to-equity ratio of 0.12, a quick ratio of 8.55 and a current ratio of 8.55.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its earnings results on Thursday, August 1st. The biotechnology company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.07). Adaptimmune Therapeutics had a negative net margin of 161.09% and a negative return on equity of 40.16%. The business had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $4.25 million. As a group, equities analysts forecast that Adaptimmune Therapeutics will post -1.17 EPS for the current year.

Large investors have recently added to or reduced their stakes in the business. D. E. Shaw & Co. Inc. acquired a new stake in shares of Adaptimmune Therapeutics during the 4th quarter valued at about $1,231,000. Baillie Gifford & Co. lifted its holdings in shares of Adaptimmune Therapeutics by 3.8% during the 1st quarter. Baillie Gifford & Co. now owns 3,839,190 shares of the biotechnology company’s stock valued at $16,508,000 after buying an additional 139,669 shares during the last quarter. Deutsche Bank AG lifted its holdings in shares of Adaptimmune Therapeutics by 1,681,328.6% during the 4th quarter. Deutsche Bank AG now owns 117,700 shares of the biotechnology company’s stock valued at $676,000 after buying an additional 117,693 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Adaptimmune Therapeutics during the 4th quarter valued at about $622,000. Finally, BlackRock Inc. lifted its holdings in shares of Adaptimmune Therapeutics by 10.4% during the 4th quarter. BlackRock Inc. now owns 856,415 shares of the biotechnology company’s stock valued at $4,924,000 after buying an additional 81,010 shares during the last quarter. 66.27% of the stock is currently owned by institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.

Further Reading: Should You Consider an Index Fund?

Analyst Recommendations for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.